Bioanalytics - Chemical

(W0930-06-32) A Sensitive Method for the Detection and Quantitation of Nalmefene in Human Plasma Samples for Pharmacokinetic Analysis

(M0930-06-32) Development of Quantitative MALDI Mass Spectrometry Imaging Methods for Studying Distribution of Antituberculosis Drugs at Their Site of Action

(M0930-06-35) Harnessing Camel Milk-Derived Exosomes to Enhance Oral Bioavailability of Anticancer Agents with Poor Solubility and Permeability (ARV-825 and CBD) and Revealing the Mechanism of Improved Absorption

(T0930-06-36) Development of a Novel LC-MS/MS Method for Quantitation of a Therapeutic Aptamer in Rat Plasma

(W0930-06-36) ICH M10 Bioanalytical Method Validation for Quantitation of Ketorolac in Human Vitreous and Aqueous Humor using Human Plasma as a Surrogate Matrix

(M1030-06-32) Analytical Considerations of Drug Products Containing Isomeric Active Pharmaceutical Ingredients in Abbreviated New Drug Application (ANDA) Submissions

(M1030-06-33) The Application of 19F-NMR in the Analysis of Drug-Related Substances of Leritrelvir (RAY1216) in Human Urine and Fecal Samples to Support a Phase I Clinical Study

(M1030-06-34) In Vitro Permeation Test Outlier Data Evaluation during Bioequivalence Assessment of Abbreviated New Drug Applications

(T1030-06-35) A Validated LC-MS/MS Assay for the Simultaneous Determination of Nebivolol, Dasatinib and Devimistat and Its Application to Pharmacokinetic Study in Rats

(M1030-06-35) Development and Optimization of a Highly Sensitive and Selective Anion Exchange Liquid Chromatography with Fluorescence Detection Assay for Quantitation of siRNA Oligonucleotide Therapeutic Compounds

(W1030-06-35) Pharmacologically Active Drug Metabolites: Impact on Drug Discovery

(W1030-06-36) Development of a Rapid, High Throughput Quantitative Bioanalysis of Conjugated Payloads of Protease-Cleavable Antibody-Drug Conjugate (ADC) in Rat Serum Using Automated Immunocapture Based UPLC-MS/MS

(M1030-06-36) Simultaneous Determination of Metabolites from Seven Key Probe Substrates in CYP Inhibition Assay Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

(M1130-06-32) A Chilled Liquid Handler Deck Enables the Automation of Lipid LC-MS/MS Bioanalytical Assays

(T1230-06-33) Development and Validation of LC-MS/MS Assay Methods to Determine Ubrogepant and Atogepant in Human Breast Milk

(M1330-06-32) Quantifying and Mapping ATP Distribution Within Tissues to Inform Targeted Therapeutic Strategies in Drug Development

(M1330-06-35) In Vitro Irritability, Toxicity, and Anti-Inflammatory Activity of Rosehip Oil Emulsion

(T1430-06-31) Automated Supporting Liquid Extraction (SLE) Workflow to Extract Zolmitriptan from Plasma Samples for Bioanalysis

(T1430-06-33) Comparison of the Pharmacokinetics and Metabolic Fate of Gefitinib – 3 – PROTACs and Gefitinib in the Rat Following Subcutaneous Dosing

(M1430-06-34) Validated Biomarker Assay for the Analysis of Coproporphyrin I and Coproporphyrin III in Human Plasma

(M1430-06-35) Avoiding Pitfalls in Selecting Quality Control Concentrations in Surrogate Matrix Approach for Endogenous Drugs